managing toxicities associated with immunotherapy in multiple myeloma
Published 6 months ago • 125 plays • Length 1:29Download video MP4
Download video MP3
Similar videos
-
3:09
an overview of the toxicities associated with immunotherapy in multiple myeloma
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
2:35
resistance to immunotherapy in multiple myeloma: mechanisms & monitoring
-
2:26
the role of immunotherapy in multiple myeloma
-
3:10
immunotherapy for the treatment of multiple myeloma
-
5:33
cancer immune checkpoint inhibitors
-
2:38
how close is a cure for multiple myeloma?
-
7:25
how to manage toxicities from immune checkpoint inhibitors?
-
2:35
updates in immunotherapy for multiple myeloma
-
2:05
checkpoint inhibitors: parallel management of the disease and immune-related toxicities
-
3:09
immunotherapy in myeloma - where are we?
-
5:06
advances in immunotherapy for multiple myeloma and future outlooks
-
1:35
rationale for using immunotherapies in the frontline treatment of multiple myeloma
-
3:11
sequencing immunotherapies in multiple myeloma
-
2:15
novel immunotherapies for the treatment of multiple myeloma
-
3:43
mrd-guided treatment cessation in multiple myeloma
-
5:25
novel immunotherapies for multiple myeloma
-
0:36
the potential of immunotherapies in the myeloma treatment landscape
-
1:42
optimal sequencing of immunotherapies to improve outcomes for patients with multiple myeloma
-
1:53
toxicities and new immune checkpoint inhibitors
-
1:57
sequencing immunotherapies in multiple myeloma
-
2:53
immune profiling in patients with multiple myeloma treated with cellular therapies